CLARITY-NJ Alzheimer's Study Reaches 50% Enrollment Milestone

We're proud to announce that our CLARITY-NJ study evaluating a monthly anti-amyloid infusion for early Alzheimer's disease has reached 50% of its enrollment target ahead of schedule.

This milestone reflects the trust our Bergen County community places in clinical research. Every participant in this study is contributing to what could become one of the most important Alzheimer's treatments of the decade.

Screening visits remain available for adults aged 60–85 with mild cognitive impairment. A study partner and confirmed amyloid pathology are required — our coordinators can help arrange the necessary PET imaging at no cost.